These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30036587)

  • 1. The Machado-Joseph disease-associated expanded form of ataxin-3: Overexpression, purification, and preliminary biophysical and structural characterization.
    Contessotto MGG; Rosselli-Murai LK; Garcia MCC; Oliveira CLP; Torriani IL; Lopes-Cendes I; Murai MJ
    Protein Expr Purif; 2018 Dec; 152():40-45. PubMed ID: 30036587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the structure and the amyloidogenic properties of the Josephin domain of the polyglutamine-containing protein ataxin-3.
    Masino L; Nicastro G; Menon RP; Dal Piaz F; Calder L; Pastore A
    J Mol Biol; 2004 Dec; 344(4):1021-35. PubMed ID: 15544810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Examination of Ataxin-3 (atx-3) Aggregation by Structural Mass Spectrometry Techniques: A Rationale for Expedited Aggregation upon Polyglutamine (polyQ) Expansion.
    Scarff CA; Almeida B; Fraga J; Macedo-Ribeiro S; Radford SE; Ashcroft AE
    Mol Cell Proteomics; 2015 May; 14(5):1241-53. PubMed ID: 25700012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capturing the Conformational Ensemble of the Mixed Folded Polyglutamine Protein Ataxin-3.
    Sicorello A; Różycki B; Konarev PV; Svergun DI; Pastore A
    Structure; 2021 Jan; 29(1):70-81.e5. PubMed ID: 33065068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polyglutamine-Independent Features in Ataxin-3 Aggregation and Pathogenesis of Machado-Joseph Disease.
    Carvalho AL; Silva A; Macedo-Ribeiro S
    Adv Exp Med Biol; 2018; 1049():275-288. PubMed ID: 29427109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re-establishing ataxin-2 downregulates translation of mutant ataxin-3 and alleviates Machado-Joseph disease.
    Nóbrega C; Carmo-Silva S; Albuquerque D; Vasconcelos-Ferreira A; Vijayakumar UG; Mendonça L; Hirai H; de Almeida LP
    Brain; 2015 Dec; 138(Pt 12):3537-54. PubMed ID: 26490332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flanking domain stability modulates the aggregation kinetics of a polyglutamine disease protein.
    Saunders HM; Gilis D; Rooman M; Dehouck Y; Robertson AL; Bottomley SP
    Protein Sci; 2011 Oct; 20(10):1675-81. PubMed ID: 21780213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyglutamine expansion diseases: More than simple repeats.
    Silva A; de Almeida AV; Macedo-Ribeiro S
    J Struct Biol; 2018 Feb; 201(2):139-154. PubMed ID: 28928079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease.
    Matos CA; de Macedo-Ribeiro S; Carvalho AL
    Prog Neurobiol; 2011 Sep; 95(1):26-48. PubMed ID: 21740957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance.
    Li X; Liu H; Fischhaber PL; Tang TS
    Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Machado-Joseph disease-associated form of ataxin-3 impacts dynamics of clathrin-coated pits.
    Rosselli-Murai LK; Joseph JG; Lopes-Cendes I; Liu AP; Murai MJ
    Cell Biol Int; 2020 May; 44(5):1252-1259. PubMed ID: 31970864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced molecular mobility of ordinarily structured regions drives polyglutamine disease.
    Lupton CJ; Steer DL; Wintrode PL; Bottomley SP; Hughes VA; Ellisdon AM
    J Biol Chem; 2015 Oct; 290(40):24190-200. PubMed ID: 26260925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Machado-Joseph Disease: A Stress Combating Deubiquitylating Enzyme Changing Sides.
    Dantuma NP; Herzog LK
    Adv Exp Med Biol; 2020; 1233():237-260. PubMed ID: 32274760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a novel site of interaction between ataxin-3 and the amyloid aggregation inhibitor polyglutamine binding peptide 1.
    Knight PD; Karamanos TK; Radford SE; Ashcroft AE
    Eur J Mass Spectrom (Chichester); 2018 Feb; 24(1):129-140. PubMed ID: 29334808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of the polyglutamine protein ataxin-3 with Rad23 regulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3.
    Sutton JR; Blount JR; Libohova K; Tsou WL; Joshi GS; Paulson HL; Costa MDC; Scaglione KM; Todi SV
    Hum Mol Genet; 2017 Apr; 26(8):1419-1431. PubMed ID: 28158474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mass spectrometry analyses of normal and polyglutamine expanded ataxin-3 reveal novel interaction partners involved in mitochondrial function.
    Kristensen LV; Oppermann FS; Rauen MJ; Fog K; Schmidt T; Schmidt J; Harmuth T; Hartmann-Petersen R; Thirstrup K
    Neurochem Int; 2018 Jan; 112():5-17. PubMed ID: 29111377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Polyglutamine-expanded ataxin-3 is degraded by autophagy].
    Xiao H; Tang J; Hu Z; Tan J; Tang B; Jiang Z
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):23-8. PubMed ID: 20140862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3.
    Haacke A; Broadley SA; Boteva R; Tzvetkov N; Hartl FU; Breuer P
    Hum Mol Genet; 2006 Feb; 15(4):555-68. PubMed ID: 16407371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PolyQ-expanded ataxin-3 protein levels in peripheral blood mononuclear cells correlate with clinical parameters in SCA3: a pilot study.
    Gonsior K; Kaucher GA; Pelz P; Schumann D; Gansel M; Kuhs S; Klockgether T; Forlani S; Durr A; Hauser S; Rattay TW; Synofzik M; Hengel H; Schöls L; Rieß OH; Hübener-Schmid J
    J Neurol; 2021 Apr; 268(4):1304-1315. PubMed ID: 33106888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Machado-Joseph disease-associated mutant form of ataxin-3 regulates parkin ubiquitination and stability.
    Durcan TM; Kontogiannea M; Thorarinsdottir T; Fallon L; Williams AJ; Djarmati A; Fantaneanu T; Paulson HL; Fon EA
    Hum Mol Genet; 2011 Jan; 20(1):141-54. PubMed ID: 20940148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.